Puma Biotechnology, Inc. (PBYI) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 11/22/22
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR SymposiumBusiness Wire • 10/27/22
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A InhibitorBusiness Wire • 09/20/22
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022Business Wire • 09/11/22
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceBusiness Wire • 09/06/22
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a WoeZacks Investment Research • 08/26/22
Toragen, Inc. Announces the Appointment of Board of Directors and Senior StaffBusiness Wire • 08/15/22
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial ResultsBusiness Wire • 07/21/22
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual MeetingBusiness Wire • 06/06/22
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket' Trial of Neratinib at the ASCO 2022 Annual MeetingBusiness Wire • 06/04/22
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual MeetingBusiness Wire • 05/26/22